VWF and Cowden syndrome 1: Prednisolone increased peak thrombin, velocity index, plasminogen-activator inhibitor type-1 (PAI-1) and von Willebrand factor (VWF) compared with the placebo group, suggesting that CS treatment may contribute to thromboembolic risk [18].